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Abstract
Background: Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident
CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed.
Methods: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, we
determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months
that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated
glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. We also described the primary care, outcomes and risk factors
associated with outcomes using competing risks analyses for these CKD patients.
Results: A total of 631 incident CKD patients (stages 3 to 5) were followed-up until the occurrence of death and dialysis
initiation for more than 3 years. The annual incidence rate of CKD (stages 3 to 5) was estimated at 977.7 per million
inhabitants. Analyses were performed on 514 patients with available medical data. During the study, 155 patients (30.2 %)
were referred to a nephrologist, 193 (37.5 %) died and 58 (11.3 %) reached end-stage renal disease and initiated dialysis. A
total of 139 patients (27.6 %) had a fast decline of their renal function, 92 (18.3 %) a moderate decline and the 272
remaining patients had a physiological decline (21.1 %) or a small improvement of their renal function (33.0 %). Predictors
of death found in both Cox and Fine-Gray multivariable regression models included age at diagnosis, anemia, active
neoplasia and chronic heart failure, but not a low glomerular filtration rate (GFR). Age at diagnosis, anemia and a low GFR
were independently associated with dialysis initiation in Cox model, but anemia was not found to be a risk factor for
dialysis initiation in Fine-Gray model.
Conclusions: This large cohort study provided useful epidemiological data on incident CKD (stages 3 to 5) and stressed
the need to improve the hands-on implementation of clinical practice guidelines for the evaluation and the management
of CKD in primary care.
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Background
Chronic kidney disease (CKD) is a common condition and
the increased incidence of end-stage renal disease (ESRD)
is a growing public health challenge worldwide [1–6]. Less
than 2 % of CKD patients in all stages except stage 4 pro-
gress to ESRD and undergo renal replacement therapy
(RRT) [7]. CKD is associated with a markedly increased
risk of cardiovascular morbidity and mortality and it is
clear that the majority of CKD patients, especially those
aged 75 and over, dies before reaching ESRD largely due
to worsening heart disease [7–12].
The early identification of patients at increased risk for
CKD or in the early stages is therefore critical and could
facilitate timely therapeutic interventions to slow both
progression of CKD to ESRD and cardiovascular diseases
with benefits on both kidney and patient survival
[13, 14]. Thus screening strategies to increase early
recognition of individuals at risk were developed
implementing surveillance of elevated plasma cre-
atinine, microalbuminuria, and more recently routine
reporting of estimated glomerular filtration rate
(eGFR) in a high-risk target population [3, 15–22].
Family general practitioners (GPs) are responsible for
CKD screening and timely referral to nephrologist.
This creates opportunity for coordinated and optimal
management of CKD to reduce morbidity and mor-
tality [23].
Epidemiological data on incident CKD in the general
population are the only ones permitting non-biased
prognostic studies to be carried out, but they are scarce
[5]. A recent literature review highlighted substantial
heterogeneity between prevalence studies related to a
wide range of study designs, criteria used for the selec-
tion of patients, and methods for measuring renal func-
tion [2]. Among the 43 selected studies, 6 high-quality
studies allowed an estimate of the prevalence in a range
of 1.7 to 8.1 %.
The objectives of the present community-based study
was to determine the number of patients residing in a
well-defined geographical area having a first serum cre-
atinine value ≥1.7 mg/dL after January 1st, 2004 and still
present for at least 3 months, and to describe their
primary care, outcomes and risk factors associated with
outcomes using competing risks analyses.
Methods
Study design
EPIRAN (EPidémiologie de l’Insuffisance Rénale chroni-
que dans l’Agglomération Nancéienne) was a community-
based epidemiological study based on active and passive
data collection. The EPIRAN study was a prospective
observational cohort study. As a result, the assignment of
a human participant to a particular health-related
intervention was not designed in advance by a trial proto-
col but fell within current clinical practice.
The study was conducted in the general population from
a well-defined geographical area, the Urban Community of
Greater Nancy (UCGN). This area is located in Eastern
France and comprises a population of 258,000 inhabitants
according to the 1999 census; it has a University Hospital
and 2 private clinics.
Study population
Included patients, called incident CKD patients (stages 3
to 5), were all adult patients (≥18 years) residing in the
given geographical area and having a first serum creatin-
ine value ≥1.7 mg/dL reached after January 1st, 2004 and
present for at least 3 months.
Data collection
Our study used laboratory data from routine tests. All
16 clinical laboratories gave their agreement to partici-
pate and were asked to report electronic data on patients
fulfilling the inclusion criteria. As eGFR was not auto-
matically generated by laboratories in France in 2004, its
assessment could not be used as a diagnostic criterion.
In the absence of patient’s objection, validation of data
was conducted on 50 000 dosages that had been
declared in two and a half years. To avoid duplication
between laboratories, double-entries were systematically
checked first. Then previous creatinine levels were
screened for each patient in order to identify prevalent
CKD patients. When the first high creatinine measure-
ment was not confirmed after a 3-month period we sys-
tematically searched for a creatinine level <1.7 mg/dL.
At the end of this process, all patients with a creatinine
level ≥ 1.7 mg/dL prior to January 1st, 2004, or a level
lowered back to below 1.7 mg/dL were excluded. Only
creatinine values ≥1.7 mg/dL were systematically
reported by laboratories in the UCGN from January 1st,
2004 to June 30th, 2006.
An expert committee composed of nephrologists and
epidemiologists critically reviewed and validated all
exclusions and inclusions, and confirmed the persistence
of kidney injury for all included patients, using a stan-
dardized process.
Each prescribing physician was contacted by a study
nurse to give additional information on registration
status. Each GP was asked about history of kidney dis-
ease and nephrology care. However, some GPs refused
to provide any data about their patients. Consequently,
117 patients had missing data for all covariates except
age, sex, and creatinine level, and were excluded in stat-
istical analyses of secondary objectives.
Clinical and biochemical characteristics were collected.
eGFR was calculated using the simplified Modification
of the Diet in Renal Disease (MDRD) formula for
Ayav et al. BMC Nephrology  (2016) 17:174 Page 2 of 13
patients with creatinine level ≥1.7 mg/dL [24]. CKD
(stages 3 to 5) was defined solely by eGFR <60 mL/
minute/1.73 m2. The number of included patients
allowed us to calculate an annual incidence rate of
CKD (stages 3 to 5).
As the study was aimed to observe the management of
patients in real life, and therefore based on the strict
respect of usual GP’s medical practice, the only visits
and assessments collected by the study nurses were
those carried out and requested by GPs. GPs were there-
fore free to schedule visits, order additional laboratory
testing, and refer their patients to nephrologists.
Patients were followed-up until the occurrence of death,
dialysis initiation, move outside the study area, or the end
of the study (date of point on December 31st, 2009).
Progression of CKD during the study period was
classified as following: improvement of eGFR if the
difference between the final and initial values of
serum creatinine (fSC-iSC) was ≤0, physiological
decline if 0 < fSC-iSC ≤ 2, moderate decline if 2 < fSC-
iSC < 5 and fast decline if fSC-iSC ≥ 5 [25].
Data about nephrology care, dialysis initiation and kid-
ney transplant were collected for all included patients
from all three nephrology departments located in the
UCGN and from the French Renal Epidemiology and
Information Network (REIN) registry [26]. To identify
deaths among all included patients, the national regis-
ter of deaths was interrogated at the end of the
follow-up period [27].
Statistical analyses
The annual incidence rate of CKD (stages 3 to 5) in UCGN
was estimated from the whole study cohort (N= 631). It
was calculated using the general population estimates for a
health service catchment area as the denominator, based on
population estimates from the 1999 Census [28]. Over the
first decade of 2000, this population was unchanged [28].
Incidence rates according to gender and age were also
calculated. Standardized incidence rate was also calculated
according to direct standardization method and using
WHO European standard population as reference [29].
Statistical analyses were performed on the 514 patients
who had available characteristics. Baseline characteristics
were presented in terms of mean and standard deviation
(STD) for continuous variables, and expressed as
frequency and percentage for categorical variables.
Univariable and multivariable analyses
Death and dialysis initiation were considered as compet-
ing risks, whereas other events were censored. The
crude cumulative incidence functions were estimated for
death and dialysis initiation using the method of
Kalbfleisch and Prentice [30, 31]. We used two different
models for uni- and multivariable analyses for the
survival regression models on the whole cohort: i) a Cox
proportional hazard regression model on the cause-
specific hazards of death and of dialysis initiation, ii) a
Fine-Gray regression model on the sub-distribution
hazards of death and of dialysis initiation [32, 33].
Management of missing data
Given a large number of missing biological data, Hb
level was the only variable taken into account. There
was 11 % of missing Hb values. Values for covariates
with missing values were obtained by multiple imputa-
tions using the MICE package as recommended for a
Cox proportional hazard model analysis [34]. This was
achieved with regression switching imputation using
linear or logistic regression models dependingon the
nature of the incomplete covariate fitted [34, 35]. This
procedure was repeated five times to obtain five draws
for each missing value in five distinct datasets.
Covariates were selected in the multivariable analysis
using a stepwise procedure adapted to multiple imput-
ation methodology [36]. According to Rubin’s approach,
the coefficients and variances obtained with the final
model on each imputed dataset were averaged by taking
into account the intra-variance of the model and inter-
variance between the imputed datasets [37].
Log-linearity assumption
The log-linear assumption of the Cox proportional haz-
ard model was assessed using the Martingale residuals
[38]. Since the log-linearity assumption was violated for
age, hemoglobin (Hb) level, and eGFR, they were trans-
formed into categorical variables. The cut-off values
were identified with graphic investigations using Martingale
residuals plots, maximization of the Gray test, and on the
basis of medical expertise and consensus.
Sensitivity analysis
The cut-off value for eGFR was mainly determined by
its association with the risk of hemodialysis which could
lead to an underestimation of the relationship between
eGFR and the risk of death. A sensitivity analysis was
conducted to explore the relationship between the risk
of death and various transformations of eGFR: continu-
ous, logarithmic, or every possible cut-off of the variable.
Softwares
All statistical calculations were performed on SAS© v
9.2 (SAS Institute Inc., Cary, NC, USA) using the R stat-
istical programming language and computing environ-
ment with survival, cmprsk, and Mice packages [39].
Results
A total of 49,114 creatinine values ≥1.7 mg/dL were re-
ported in the UCGN from January 1st, 2004 to June 30th,
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2006. Among the 4,409 individuals, 35 patients refused to
be enrolled and 110 were excluded because of lack of a
second creatinine measurement; 1,012 patients with a
serum creatinine ≥1.7 mg/dL reported prior to January 1st
2004 were considered as prevalent CKD patients; 2,621
patients had an acute deterioration of renal function, and
creatinine level lowered back to below 1.7 mg/dL during
the follow-up; finally, 631 were diagnosed incident CKD
patients after validation by the expert committee (Fig. 1).
The first serum creatinine measurement with a value
≥1.7 mg/dL was initiated by a GP for 45.0 % of the 631
cases, a non nephrologist specialist for 49.5 %, and a neph-
rologist for only 5.5 %. Reasons why a specialist ordered a
creatinine blood test were mostly a standard medical
checkup on planned admission to hospital (57.8 %), on
emergency visit (15.7 %), on pre-anesthesia assessment
(12.8 %) and a routine follow-up for a chronic condition
(13.7 %). A period of time was needed before confirmation
of diagnosis by a second creatinine determination, and
was similar for GPs and non nephrologist specialists
(7 ± 4.2 and 6.4 ± 4.3 months, respectively).
Incidence rate of CKD (stages 3 to 5)
The annual incidence rate of CKD was estimated from
the whole cohort (N= 631) at 977.7 per million population
(pmp) [902.9–1,057.0], approximately two-fold higher in
men than in women (1,338.2 [1,211.5–1,474.6] and 654.9
pmp [571.7–746.7], respectively). Standardized incidence
according to the WHO population-type was 767.1 pmp
[764.0–770.1].
Incidence rate of CKD was very low under age 45 and
increased exponentially after age 55 (mean age: 76.4 ±
12.8 years), with a male preponderance regardless of age
(Fig. 2). The sex ratio male/female (1.83) decreased pro-
gressively with age from 3.89 for patients aged 55–65 to
1.89 for patients aged >95.
Baseline characteristics
As some GPs refused to participate in the study, medical
data were available for only 514 patients and used for
the secondary objective (Fig. 1). We compared demo-
graphic characteristics of CKD patients with and without
additional medical data and the only difference con-
cerned age: 75.95 ± 13.05 vs. 78.52 ± 11.56 years, respect-
ively p = 0.0467. Baseline characteristics of the 514
patients are displayed in Table 1. The majority of
patients (73.9 %) were aged ≥70 years at the time of
diagnosis and 65.4 % were men.
About one-third of patients were diabetic and one-
quarter had congestive heart failure (CHF). Estimated
GFR was 32 ± 8.6 mL/min/1.73 m2. All patients were
CKD diagnosed at stage 3 (61.1 %), stage 4 (32.7 %) and
stage 5 (6.2 %). At inclusion, Hb level was 12.1 ± 2.1 g/dL;
more than half of the patients were anemic (Hb level
Fig. 1 Flow diagram of patient distribution according to their status. a Chronic kidney disease; b Acute kidney injury
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<12 g/dL for women, <13 g/dL for men). Proteinuria was
measured in only 9.7 % of patients (n = 50). The mean
value for proteinuria was 2.1 ± 2.8 g/24 h (median value:
1.2 g/24 h). At the time of the first serum creatinine
value > 1.7 mg/dL, 15 % of patients had already attended a
nephrologist consultation, and 19.6 % of patients had had
a serum creatinine measurement as part of their follow-up
care for a known nephropathy.
Outcomes
Patients were followed-up for more than three years
(37.9 ± 24.0 months). During the course of the study, a
total of 155 patients (30.2 %) were referred to a neph-
rologist within 16.0 ± 16.2 months after being included,
193 (37.5 %) died and 58 (11.3 %) reached ESRD and
initiated dialysis (no preemptive kidney transplantation).
Among those who died, only 17.1 % were referred to a
nephrologist. The leading causes of death were: cardio-
vascular diseases (32.3 %), cancer (28.6 %), other or
unknown (15.3 %) and infectious diseases (8.5 %). The
five-year probabilities of death and dialysis initiation
reached 33 % and 12 %, respectively (Fig. 3).
A total of 139 patients (27.6 %) had a fast decline of
their renal function, 92 (18.3 %) a moderate decline and
the 272 remaining patients had a physiological decline
(21.1 %) or a small improvement of their renal function
(33 %) (Table 2). Fast progressors were more likely to
reach ESRD or death (p < 0.0001).
Competing risk analyses of death and dialysis initiation
Variables associated with death using Cox univariable
regression analysis were age at diagnosis, Hb level
<11 g/dL, active neoplasia and CHF (Table 3).
They remained independently associated with death in
the Cox multivariable regression analysis (Table 4). No
other variables associated with death as those identified
in the Cox model were significant in the Fine-Gray
model (Table 4). eGFR was not found to be a risk factor
for death in the main analysis (Table 4, Fig. 4-Panel a)
and in the sensitivity analysis.
Variables associated with dialysis initiation using Cox
univariable regression analysis were: age at diagnosis, Hb
level <11 g/dL, diabetes, and eGFR <20 mL/min
(Table 3). In the Cox multivariable regression analysis,
age at diagnosis, Hb level <11 g/dL, and eGFR <20 mL/
min remained independently associated with dialysis
initiation (Table 3, Fig. 4-Panel b). No other variables
associated with dialysis initiation as those identified in
the Cox model were significant in the Fine-Gray univari-
able analysis. In the Fine-Gray multivariable model, Hb
level <11 g/dL was not found to be a risk factor for
dialysis initiation (Table 4).
Discussion
In the population-based EPIRAN study, we detected
patients having two consecutive serum creatinine values
≥1.7 mg/dL over a three-month period. Each case was
Fig. 2 Cumulative incidence of chronic kidney disease according to age at diagnosis and gender. pmp: per million population
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critically reviewed by an expert committee. The annual
incidence rate of CKD (stage 3 to 5 CKD defined as
eGFR < 60 ml/min/1.73 m2/year) was estimated to 977.7
pmp using routine blood testing systematically reported
by clinical laboratories of an urban territory with a
population of 250,000. The incidence was two-fold
higher in men than in women. This result is not
surprising given the fact that the same cut-off was used
in both genders. The identified patients were elderly
with multiple comorbidities. Our results were close to
that previously observed [40]. Studies conducted to de-
fine incidence for CKD are scarce, most of studies evalu-
ate its prevalence [3–5, 40]. Prevalence studies indicate
CKD burden whereas incidence studies contribute to the
Table 1 Baseline characteristics of incident CKD patients with available data (N = 514)
Missing data (%) N % Mean STD Median Q1 Q3 Min Max
Age (year) 0 514 76.0 13.0 77.7 69.6 84.9 17.5 99.9
< 70 134 26.1
70–80 156 30.4
80–85 96 18.7




BMI (kg/m2) 36.9 324 27.1 5.4 26.1 23.7 30.1 14.7 47.5
≤ 20 21 6.5
]20–25] 97 29.9
]25–30] 122 37.7
> 30 84 25.9
SBP (mm Hg) 36.4 327 136.8 22.8 135 120 150 78 240
DBP (mm Hg) 36.4 327 73.3 12.6 70 66 80 38 120






Cardiovascular diseases 436 86.0
Diabetes mellitus 173 34.1
Ischemic cardiomyopathy 159 31.4
Heart failure (NYHA III or IV) 117 23.1
Hypertension 368 72.6
Stroke 45 8.9
Lower limb peripheral arterial disease 101 19.9
Neoplasia 87 17.2
Hemoglobin (g/dL) 11.3 454 12.1 2.1 12.1 10.6 13.5 5.4 18.4
Serum creatinine (mg/dL) 0 514 2.2 1.3 1.9 1.8 2.1 1.7 23.7
eGFR (mL/min/1.73 m2) 0 514 32.0 8.6 32.4 27.3 38.9 1.7 52.8




BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate using MDRD formula (Modification of the Diet in Renal Disease), Min
minimum, Max maximum, Q1 quartile 1, Q2 quartile 2, STD standard deviation, SDB systolic blood pressure
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implementation of longitudinal follow-up and the moni-
toring of CKD progression, and may therefore suggest
prevention strategies.
One of the major strengths of our study is the innova-
tive nature of the methodology based on repeated meas-
urement of serum creatinine to confirm the persistence
of renal injury. Firstly, it is worth noting that the system-
atic and automated self-reporting of abnormal creatinine
levels above the cut-off value by laboratories may help
primary care physicians detect more accurately patients
at increased risk for CKD or in early stages, particularly
among elderly [16, 22, 41, 42]. Secondly, asserting inci-
dence and chronicity of the condition is of major
interest to differentiate CKD from acute kidney injury
(AKI) and not misclassify patients with an acute deteri-
oration as chronic. Nearly 60 % of patients with at least
one increased value in creatinine level above 1.7 mg/dL
had creatinine level under this cut-off value during the
course of our study. All medical reports were appraised
by an expert committee including nephrologists and
epidemiologists. Study nurses systematically interviewed
all clinical laboratories in order to track all measures
under the cut-off value that would not have been re-
ported. This work allowed us to assert the chronicity of
renal disease. Thirdly, the large sample size and the pro-
spective non interventional design with a longitudinal
Fig. 3 Cumulative incidence of death and dialysis initiation during the follow-up. The cumulative incidence curves are stacked
Table 2 Progression of CKD according to the renal function during the study period (N = 503)
Annual progression of CKD Patient’s condition at the end of the study
N (%) Without ESRD ESRD Death Total
Improvement of renal functiona 96 (57.8 %) 12 (7.2 %) 58 (35 %) 166
Physiological declineb 74 (69.8 %) 5 (4.7 %) 27 (25.5 %) 106
Moderate declinec 48 (52.2 %) 12 (13 %) 32 (34.8 %) 92
Rapid declined 39 (28.1 %) 29 (20.9 %) 71 (51.0 %) 139
Total 257 58 188 503
CKD chronic kidney disease, ESRD end-stage renal disease
aif the difference between the final and initial values of serum creatinine (fSC-iSC) was ≤0
bif 0 < fSC-iSC ≤ 2
cif 2 < fSC-iSC < 5
dif fSC-iSC ≥ 5
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follow-up add to the robustness of our findings reflect-
ing real life. Finally, competing risks analyses showed
that most patients died prior to the stage of ESRD and
allowed us to identify predictive factors associated to
death and dialysis initiation. Age at diagnosis, presence
of anemia, CHF and active neoplasia were independent
Table 3 Risk factors associated with death and dialysis initiation (univariable analyses)
Cox model Fine-Gray model
Variables Death Dialysis initiation Death Dialysis initiation
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Age (years)
< 70 1.00 1.00 1.00 1.00
70–80 1.91 [1.23 –2.97] 0.44 [0.23 –0.84] 2.07 [1.34 –3.22] 0 .39 [0.21 –0.75]
80–85 1.87 [1.15 –3.03] 0.30 [0.13 –0.74] 2.06 [1.28 –3.33] 0 .27 [0.11 –0.66]
> 85 2.78 [1.8 –4.32] 0.45 [0.22 –0.92] 2.98 [1.92 –4.62] 0.36 [0.17 –0.73]
Gender
Male 1.00 1.00 1.00 1.00
Female 1.13 [0.84 –1.52] 1.37 [0.81 –2.32] 1.10 [0.82 –1.49] 1.27 [0.75 –2.15]
Hemoglobin
≥ 11 g/dL 1.00 1.00 1.00 1.00
< 11 g/dL 2.37 [1.76 –3.17] 2.52 [1.44 –4.41] 2.13 [1.59 –2.86] 1.89 [1.09 –3.29]
Cancer < 5 years
No 1.00 1.00 1.00 1.00
Yes 1.67 [1.18 –2.35] 0.95 [0.45 –2.01] 1.62 [1.14 –2.32] 0.78 [0.37 –1.67]
Chronic heart failure
No 1.00 1.00 1.00 1.00
Yes 1.74 [1.29 –2.36] 0.68 [0.33 –1.38] 1.78 [1.32 –2.4] 0.59 [0.29 –1.19]
Ischemic cardiopathy
No 1.00 1.00 1.00 1.00
Yes 1.28 [0.95 –1.72] 0.80 [0.44 –1.43] 1.30 [0.97 –1.74] 0.75 [0.42 –1.34]
Stroke
No 1.00 1.00 1.00 1.00
Yes 1.45 [0.94 –2.25] 0.57 [0.18 –1.84] 1.48 [0.96 –2.3] 0.52 [0.16 –1.68]
Peripheral arterial disease
No 1.00 1.00 1.00 1.00
Yes 1.07 [0.76 –1.52] 1.55 [0.87 –2.75] 1.03 [0.73 –1.44] 1.59 [0.9 –2.81]
Diabetes
No 1.00 1.00 1.00 1.00
Yes 0.92 [0.68 –1.25] 2.54 [1.51 –4.28] 0.88 [0.65 –1.18] 2.62 [1.56 –4.41]
High blood pressure
No 1.00 1.00 1.00 1.00
Yes 0.82 [0.6 –1.11] 0.85 [0.48 –1.5] 0.85 [0.62 –1.15] 0.90 [0.51 –1.58]
Others
No 1.00 1.00 1.00 1.00
Yes 1.56 [0.96 –2.53] 1.18 [0.54 –2.61] 1.54 [0.94 –2.52] 1.08 [0.49 –2.39]
eGFR
> 20 mL/min 1.00 1.00 1.00 1.00
< 20 mL/min 1.30 [0.77 –2.2] 6.93 [3.96 –12.13] 0.85 [0.49 –1.48] 6.04 [3.39 –10.74]
X variables entered into the multivariable analyses
CI confidence interval, eGFR estimated glomerular filtration rate using MDRD formula (Modification of the Diet in Renal Disease), HR hazard ratio
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Table 4 Risk factors associated with death and dialysis initiation (multivariable analyses). Covariates were selected in the multivariable
analysis using a stepwise procedure adapted to multiple imputation methodology
Death Dialysis
Cox model Fine-Gray model Cox model Fine-Gray model
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Age (years) Age (yrs)
< 70 1.00 1.00 < 70 1.00 1.00
70 –80 1.85 [1.19 –2.89] 2.07 [1.32 –3.23] 70 –80 0.34 [0.17 –0.65] 0.30 [0.16 –0.58]
80 –85 1.78 [1.09 –2.91] 2.03 [1.24 –3.31] 80 –85 0.33 [0.14 –0.81] 0.33 [0.14 –0.78]
> 85 2.56 [1.64 –4.00] 2.84 [1.82 –4.43] > 85 0.53 [0.25 –1.10] 0.40 [0.18 –0.88]
Hemoglobin Hemoglobin
≥ 11 g/dL 1.00 1.00 ≥ 11 g/dL 1.00 1.00
< 11 g/dL 2.18 [1.61 –2.93] 2.01 [1.49 –2.73] < 11 g/dL 2.05 [1.16 –3.60] 1.62 [0.92 –2.84]
Cancer < 5 years eGFR
No 1.00 1.00 ≥ 20 mL/min 1.00 1.00
Yes 1.61 [1.14 –2.28] 1.62 [1.1 –2.37] < 20 mL/min 8.13 [4.37 –15.13] 8.32 [4.4 –15.71]
Chronic Heart Failure Diabetes
No 1.00 1.00 No 1.00 1.00
Yes 1.72 [1.26 –2.34] 1.81 [1.31 –2.49] Yes 3.41 [1.92 –6.07] 3.43 [1.93 –6.09]
Stroke
No 1.00 1.00
Yes 1.46 [0.93 –2.28] 1.44 [0.89 –2.32]
High Blood Pressure
No 1.00 1.00
Yes 0.76 [0.55 –1.04] 0.80 [0.58 –1.11]
CI confidence interval, HR hazard ratio
Fig. 4 Cumulative incidence of death (Panel a: on the left side) and end-stage renal disease (ESRD) (Panel b: on the right side) in patients with
eGFR <20 mL/min/1.73 m2 (solid line) and other patients (dotted line). HD: hemodialysis; eGFR: estimated glomerular filtration rate (using MDRD-
modification of diet in renal disease-formula)
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risk factors for all-cause mortality. Our results are con-
sistent with those previously reported [7]. Anemia de-
velops as a frequent complication of CKD, and can have
a deleterious effect not only on progression of CKD but
also on progression of cardiovascular diseases and events
[1]. In our study, 45.9 % of incident CKD patients (stages
3 to 5) experienced decline of their renal function during
the course of the study, and those with a fast decline
were more likely to reach ESRD or death, as previously
shown among prevalent CKD patients [10, 43]. In
addition, eGFR was not associated with risk of death that
was inconsistent with previous findings [10, 44]. Go et al
found non linear relations between the GFR and the risk
of death [10]. In 38,520 non-dialysis-dependent CKD pa-
tients, each 5 mL/min/1.73 m2 decline in eGFR was as-
sociated with higher risk of death due to cardiovascular
disease (hazard ratio: 1.10; 95 % confidence interval: 1.08
to 1.12) [44]. The first possible explanation for our
contradictory results is the selection of incident patients
whereas those previous studies included prevalent pa-
tients. All the published data that correlated eGFR with
death were observed in studies performed in prevalent
CKD patients. Prevalent CKD patients are different from
incident CKD patients because of a survival bias due to
the non-inclusion of patients who have died before the
study starts and to the fact that development of CKD
increases the risk of death. A second explanation is
supported by clinical characteristics of patients in-
cluded in the EPIRAN study; they were mostly stage
3 CKD patients at the time of diagnosis and non pro-
gressors (54.1 %). From our point of view, progression
of CKD played a major role when it was found to be
associated with risk of death in prevalent patients.
Finally, a completely different explanation could be
supported by recent findings. Mandelli et al. assessed
mortality prediction in the oldest old (aged 85 years
and older) with five different equations to estimate
GFR They showed that risk of mortality was
significantly higher for reduced GFR estimated with
the Berlin Initiative Study-1 and Cockroft-Gault equa-
tions over the short time, whereas the MDRD for-
mula appeared a more consistent predictor after five
years [45]. However, a significantly higher risk of
death after 5 years was found in the oldest old with a
very low eGFR (<30 mL/min/1.73 m2), irrespective of
the equation. In addition, we found that independent
risk factors significantly associated with dialysis initi-
ation were age at diagnosis, presence of diabetes and
GFR below 20 mL/min/1.73 m2. Interestingly, elderly
(>70 years) were less likely to undergo dialysis. This
may be due to a bias towards nephrology referral and
indication for dialysis, a low likelihood of experien-
cing progression of CKD to ESRD in elderly or a
patient choice [46].
CKD patients identified in our cohort were mainly
stages 3-4 primary care patients, but the first abnormal
creatinine level (above the cut-off value) was measured
in a public or private hospital for 42.8 % of patients. For
serum creatinine measurements ordered by a non neph-
rologist specialist, they were done mostly within a stand-
ard medical checkup that was not systematically
transmitted to the family GP, and as a result, delayed
CKD diagnosis. Clinical inertia in response to CKD diag-
nosis was seen in primary care but also with specialist
care, whether they worked in healthcare institutions or
not. The same phenomenon was observed for the check
up to diagnose CKD. Proteinuria was sought only in
7.9 % of patients despite French recommendations for
diagnosis and management of CKD and international
guidelines advocating systematic screening for markers
of kidney damage such as proteinuria [47–50]. Protein-
uria is predictive for CKD progression but also for pro-
gression to ESRD [5, 48, 51–55]. Proteinuria was also
shown to impact on the occurrence of cardiovascular
events [56]. Reduction of proteinuria is therefore a major
determinant for reducing the risk of CKD progression to
ESRD and cardiovascular events [49, 57–61]. Our study
confirm that early identification of CKD patients on the
basis of presence of reduced eGFR or proteinuria is de-
sirable to permit early intervention for reducing risk of
cardiovascular events, progression to kidney failure or
death [62]. Over the past decade, the therapeutic arsenal
to reduce CKD burden, such as prevention of complica-
tions, slowing progression, and prevention of cardiovas-
cular risk, has markedly expanded [48, 50, 63]. However,
practice patterns suggest that physicians remain unfamil-
iar with recommendations for detection and manage-
ment of CKD as highlighted in several studies [64–67].
The lack of acute awareness of clinical practice guide-
lines for CKD varies according to the type of registration
status (nephrologist > specialist > GP) [65, 66]. As early
detection is within the realm of the family GPs, they
should feel more comfortable with making the initial
diagnosis of CKD and providing appropriate primary
and ongoing care to patients.
Regarding medical monitoring of patients, our findings
demonstrated that only 28.3 % of patients were referred
to a nephrologist after CKD diagnosis. There is probably
a bias in nephrologist referral related to the age of
patients. It is indeed possible that GPs chose not to refer
elderly to nephrologists because 1) they felt that elderly
could not be candidates for RRT, and 2) reduced GFR
remained relatively stable in most of them. Several
recent studies showed the benefit of conservative
management in elderly as long as they remained asymp-
tomatic [68]. A prospective, community-based study pro-
vided a compelling evidence for a causal relationship
between pre-ESRD medical care and outcomes [69].
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A recent literature review focusing on studies
regarding changes in kidney function over time
highlighted the importance of incorporating the rate
of kidney decline in the staging of CKD for better
risk stratification on mortality and cardiovascular out-
comes for individual patients as CKD is a dynamic
[70]. Although most CKD patients will die from car-
diovascular disease rather than progress to kidney
failure, it is of interest to develop prevention pro-
grams for patients who will progress to ESRD, such
as tertiary preventive care and regular monitoring to
detect early patients most likely to progress. This will
let appropriate referral of patients who might benefit
from a nephrology service while allowing the majority
to remain in primary care, and prevent that local
nephrology services become overwhelmed [71]. Never-
theless, it is mandatory to conduct medical surveil-
lance in those remaining in primary care, and avoid
all situations (iatrogenic and not) which may lead to
worsening of renal function or decompensate.
The following limitations should be considered.
First, we used a single creatinine cut-off value as in-
clusion criterion to define impaired renal function
because French clinical laboratories did not calculate
eGFR when we designed the study. Although French
clinical laboratories were required to report eGFR for
each creatinine value in 2005, we could not change
this main inclusion criterion during the study. The
creatinine cut-off value of 1.7 mg/dL was selected on
the basis of the only published incidence study when
the EPIRAN study was designed [40]. Drey et al. used
this value as recommended by the Renal Association
[72]. CKD diagnosis could only be assigned to pa-
tients who had had serum creatinine measurement,
and more specifically those who had repeated meas-
urement. As a result, incidence of CKD may be
underestimated, because only patients with serum cre-
atinine repeated measurement were included in our
study. However, this cut-off value allowed to detect a
majority of new patients having stage 3 CKD and
avoid misclassification of healthy elderly people with
eGFR <60 mL/min. Second, because of the non inter-
ventional design of our study, only patients who were
prescribed creatinine measurement could be identi-
fied. Another limitation was the scarcity of protein-
uria determination, although presence of proteinuria
was recognized to predispose to ESRD, even with a
normal renal function [3, 5, 13, 55, 57, 59, 60]. Our
results were consistent with previous findings
highlighting that special attention must be paid to
improve albuminuria screening [3, 5]. Despite these
limitations, a non interventional approach is the only
possible way of studying management of patients in
real life.
Conclusion
In conclusion, our study provided annual incidence rate
of CKD stage 3 to 5 in a community-based population,
confirmed that death was far more likely than advance-
ment to RRT in CKD patients, identified predictors of
death and dialysis initiation, and highlighted the need to
improve the hands-on implementation of guidelines for
the evaluation and management of CKD in primary care.
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